R & D

Our R&D is singularly focused on developing medicines to reverse the escalating NASH epidemic. NASH is a disease involving the whole body, requiring treatment of the imbalanced metabolism, as well as acting directly on the liver. This approach addresses not only the underlying metabolic causes but also the downstream pathological pathways leading to liver cirrhosis, liver failure and death.